DelveInsight's 'Myelodysplastic Syndrome Pipeline Insights 2025' report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in the Myelodysplastic Syndrome (MDS) pipeline landscape. The report covers drug profiles across clinical and nonclinical stages, assessing therapies by product type, stage of development, route of administration, and molecule type. It also highlights inactive pipeline products.\n\nKey takeaways include:\n- In August 2025, Novartis Pharmaceuticals announced a study evaluating the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk MDS.\n- H. Lee Moffitt Cancer Center and Research Institute conducted a multi-institution, open-label, Phase 1b/2 trial evaluating canakinumab in combination with darbepoetin alfa in lower-risk MDS patients who have failed prior ESA treatment.\n\nThe report identifies leading MDS companies such as Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, and Bellicum Pharmaceuticals.\n\nPromising therapies under development include Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, and Epoetin Alfa.\n\nEmerging drug profiles:\n- Tamibarotene (Syros Pharmaceuticals): An oral selective retinoic acid receptor alpha (RAR) agonist being evaluated in the Phase III SELECT-MDS-1 trial for newly diagnosed higher-risk MDS patients with RARA overexpression.\n- RVU120 (Ryvu Therapeutics): A selective CDK8/CDK19 inhibitor in Phase II development for MDS treatment, showing antileukemic potential in preclinical studies.\n- Emavusertib (Curis): A small-molecule IRAK4 kinase inhibitor in Phase I/II development, blocking leukemic growth in non-clinical experiments; developed through a collaboration with Aurigene.\n- MNV-201 (Minovia Therapeutics): An investigational cell therapy using Mitochondrial Augmentation Technology (MAT) to enrich hematopoietic stem and progenitor cells with mitochondria from allogeneic placental sources, currently in a Phase I clinical trial (NCT06465160) for low-risk MDS.\n\nThe report provides detailed therapeutic assessments by development stage (early, mid, late), route of administration (oral, intravenous, subcutaneous, parenteral, topical), molecule type (small molecule, monoclonal antibody, recombinant fusion proteins, peptide, gene therapy), and treatment approach (monotherapy, combination therapy). It also analyzes collaborations, licensing agreements, and financing activities shaping the MDS market.\n\nThe scope includes global coverage, with detailed insights into key companies, drug pipelines, unmet needs, market drivers and barriers, and future perspectives. The report aims to support stakeholders with real-time intelligence on innovation, clinical advancements, and strategic positioning in the evolving MDS pharmaceutical landscape.

Myelodysplastic Syndrome Pipeline Outlook Report 2025: Key

DelveInsight's 'Myelodysplastic Syndrome Pipeline Insights 2025' report offers a comprehensive analysis of over 120 companies and 150 pipeline drugs in the MDS therapeutic landscape. The report evaluates drug development by stage, product type, route of administration, and molecule class, highlighting both active and inactive therapies. Key clinical trials include Novartis's study on eltrombopag monotherapy in Japanese patients with lower-risk MDS and H. Lee Moffitt Cancer Center's Phase 1b/2 trial of canakinumab with darbepoetin alfa in patients who have failed prior ESA therapy. Promising therapies under development include Tamibarotene, RVU120, Emavusertib, and MNV-201. The report also details collaborations, licensing agreements, and financing activities influencing the MDS market, with global coverage and insights into unmet needs, market drivers, and future trends.